Ravi Viswanathan, 10% Owner at Adaptimmune Therapeutics PLC (ADAP), bought 12,870,000 shares at $0.70 ($9.0M) on 2017-03-27, disclosed to the SEC on 2017-03-28.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Negative factors outweigh the positive ones.
| Filing → |
| AVEO | BUY | 2018-07-20 | $491K | — | Filing → |
| AVEO | BUY | 2018-06-28 | $404K | — | Filing → |
| AVEO | BUY | 2018-05-30 | $591 | — | Filing → |